Skip to main content

Table 2 Comparison of IC50 values for concentration-effect curves of anti-malarial drugs against Plasmodium falciparum and Plasmodium vivax generated by different programs

From: Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms

  P. falciparum   P. vivax
Method Geometric mean IC50 [nM] (95 % CI) Median difference IC a50 [nM] (range) Method Geometric mean IC50 [nM] (95 % CI) Median difference IC a50 [nM] (range)
Chloroquine (n = 31) NONMEM 91.40 (74.39–108.40)   Chloroquine (n = 29) NONMEM 151.9 (124.2–179.6)  
GP 81.43 (67.67–98.00) 0.42 (−7.80 to 6.50) GP 137.8 (115.8–163.9) 0.37 (−50.0-32.0)
HNL 81.59 (67.26–98.97) 0.42 (−5.50 to 13.0) HNL 136.7 (114.3–163.5) 0.33 (−47.0 to 35.0)
ICE 82.59 (68.45–99.65) 1.50 (−5.00 to 11.0) ICE 137.4 (115.7–163.2) 1.80 (−62.0 to 10.0)
IVART 83.85 (69.20–101.6) 0.93 (−12.0 to 40.0) IVART 135.2 (113.0–161.7) 1.90 (−62.0 to 17.0)
WNL 81.40 (67.62–98.00) 0.51 (−5.40 to 5.10) WNL 136.4 (114.7–162.1) 0.18 (−63.0 to 12.0)
Piperaquine (n = 31) NONMEM 25.65 (20.79–30.50) Piperaquine (n = 28) NONMEM 26.03 (18.99–33.08)  
GP 21.77 (17.79–26.64) 0.56 (−9.60 to 3.30) GP 20.46 (15.51–26.99) −0.08 (−3.80 to 2.30)
HNL 22.35 (18.30–27.30) −0.22 (−5.10 to 13.0) HNL 21.26 (16.21–27.89) 0.68 (−4.80 to 6.90)
ICE 22.72 (18.44–27.99) 0.44 (−3.00 to 4.90) ICE 20.99 (15.99–27.54) 0.14 (−1.70 to 3.10)
IVART 22.10 (17.88–27.32) −0.02 (−11.0 to 4.90) IVART 21.34 (16.35–27.85) 0.24 (−2.20 to 3.80)
WNL 21.93 (17.92–26.85) −0.28 (−9.20 to 3.30) WNL 20.64 (15.68–27.18) −0.05 (−1.80 to 1.70)
Mefloquine (n = 31) NONMEM 13.49 (10.26–16.71)   Mefloquine (n = 29) NONMEM 21.67 (15.23–28.11)  
GP 10.99 (8.55–14.11) 0.01 (−1.30 to 2.90) GP 16.53 (12.12–22.56) 0.27 (−0.81 to 4.40)
HNL 11.31 (8.85–14.45) 0.24 (−0.89 to 3.80) HNL 16.61 (12.24–22.54) 0.26 (−2.30 to 3.40)
ICE 11.31 (8.84–14.46) 0.38 (−0.15 to 2.80) ICE 16.82 (12.38–22.87) 0.56 (−0.32 to 3.20)
IVART 10.59 (8.14–13.76) 0.03 (−5.10 to 3.10) IVART 16.61 (12.00–23.00) 0.51 (−2.50 to 5.40)
WNL 11.04 (8.59–14.17) 0.03 (−0.82 to 2.30) WNL 16,341 (12.01–22.43) 0.12 (−1.20 to 3.00)
Amodiaquine (n = 30) NONMEM 14.53 (12.18–16.88)   Amodiaquine (n = 28) NONMEM 24.97 (20.29–29.64)  
GP 13.40 (11.21–16.03) −0.05 (−2.70 to 11.0) GP 22.03 (17.4–27.80) 0.04 (−3.60 to 8.00)
HNL 13.59 (11.42–16.18) 0.46 (−2.80 to 2.60) HNL 22.31 (17.66–28.18) 1.10 (−2.10 to 4.50)
ICE 13.24 (11.16–15.71) 0.04 (−1.10 to 0.87) ICE 21.74 (17.34–27.25) 0.07 (−1.80 to 0.81)
IVART 13.24 (11.16–15.71) 0.04 (−1.10 to 0.87) IVART 21.88 (17.31–27.10) −0.03 (−1.80 to 0.81)
WNL 13.38 (11.22–15.96) −0.04 (−1.30 to 11.0) WNL 21.88 (17.36–27.57) −0.02 (−2.20 to 4.30)
Artesunate (n = 31) NONMEM 5.43 (3.23–7.63)   Artesunate (n = 28) NONMEM 4.12 (2.38 to 5.85)  
GP 3.59 (2.48–5.19) 0.01 (−0.14 to 1.10) GP 2.47 (1.63–3.75) 0.01 (−0.64 to 0.82)
HNL 3.57 (2.52–5.07) −0.01 (−2.60 to 11.0) HNL 2.55 (1.69–3.85) 0.06 (−0.73 to 2.60)
ICE 3.51 (2.48–4.67) 0.05 (−0.14 to 0.99) ICE 2.50 (1.65–3.79) 0.04 (−0.30 to 0.79)
IVART 3.54 (2.54–4.94) 0.07 (−2.90 to 0.84) IVART 2.45 (1.61–3.72) 0.01 (−0.63 to 0.43)
WNL 3.61 (2.49–5.23) 0.01 (−0.40 to 10.0) WNL 2.48 (1.63–3.76) 0.01 (−0.41 to 1.00)
  1. aMedian difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison